The cream ultimately rises to the top, or so that is the case with Tristel. You see, despite fears over the global economy, NHS budgetary constraints and BREXIT, the company this morning said that it had enjoyed a “very strong” 2 nd half – reporting H2 revenues of >£9m, up 13.5% YoY. Better still, FY16 adjusted PBTA (pre SBP and unrealised forex gains) and net cash came in above expectations too, at £3.1m (+20% vs £2.6m LY) and £5.7m (vs ED at £4.5m) respectively - driven by an outstanding performance from overseas (42% of H2 sales vs 36% in H1), augmented by an encouraging rebound in UK Healthcare following a slight decline in H1.
21 Jul 2016
Excellent H2 and ahead of forecasts
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Excellent H2 and ahead of forecasts
Tristel Plc (TSTL:LON) | 442 -22.1 (-1.1%) | Mkt Cap: 210.2m
- Published:
21 Jul 2016 -
Author:
Paul Hill -
Pages:
5
The cream ultimately rises to the top, or so that is the case with Tristel. You see, despite fears over the global economy, NHS budgetary constraints and BREXIT, the company this morning said that it had enjoyed a “very strong” 2 nd half – reporting H2 revenues of >£9m, up 13.5% YoY. Better still, FY16 adjusted PBTA (pre SBP and unrealised forex gains) and net cash came in above expectations too, at £3.1m (+20% vs £2.6m LY) and £5.7m (vs ED at £4.5m) respectively - driven by an outstanding performance from overseas (42% of H2 sales vs 36% in H1), augmented by an encouraging rebound in UK Healthcare following a slight decline in H1.